PL2139512T3 - Inhibitory zaburzenia lub choroby niedokrwiennej - Google Patents

Inhibitory zaburzenia lub choroby niedokrwiennej

Info

Publication number
PL2139512T3
PL2139512T3 PL08724144T PL08724144T PL2139512T3 PL 2139512 T3 PL2139512 T3 PL 2139512T3 PL 08724144 T PL08724144 T PL 08724144T PL 08724144 T PL08724144 T PL 08724144T PL 2139512 T3 PL2139512 T3 PL 2139512T3
Authority
PL
Poland
Prior art keywords
ischemic disorder
disease inhibitors
inhibitors
disease
ischemic
Prior art date
Application number
PL08724144T
Other languages
English (en)
Inventor
Lars Edvinsson
Saema Ansar
Original Assignee
Pronas Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronas Pharma Ab filed Critical Pronas Pharma Ab
Publication of PL2139512T3 publication Critical patent/PL2139512T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08724144T 2007-03-30 2008-03-25 Inhibitory zaburzenia lub choroby niedokrwiennej PL2139512T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0700814 2007-03-30
PCT/SE2008/000218 WO2008121044A1 (en) 2007-03-30 2008-03-25 Ischemic disorder or disease inhibitors
EP08724144.4A EP2139512B1 (en) 2007-03-30 2008-03-25 Ischemic disorder or disease inhibitors

Publications (1)

Publication Number Publication Date
PL2139512T3 true PL2139512T3 (pl) 2013-09-30

Family

ID=39808527

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08724144T PL2139512T3 (pl) 2007-03-30 2008-03-25 Inhibitory zaburzenia lub choroby niedokrwiennej

Country Status (5)

Country Link
US (1) US8273771B2 (pl)
EP (1) EP2139512B1 (pl)
ES (1) ES2421605T3 (pl)
PL (1) PL2139512T3 (pl)
WO (1) WO2008121044A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2139512T3 (pl) * 2007-03-30 2013-09-30 Pronas Pharma Ab Inhibitory zaburzenia lub choroby niedokrwiennej
EA028080B1 (ru) * 2010-06-09 2017-10-31 Дана-Фарбер Кэнсер Инститьют, Инк. Мутация в mek1, придающая устойчивость к ингибиторам raf и mek
US20190076510A1 (en) * 2017-09-13 2019-03-14 The Regents Of The University Of Michigan Protein kinase c inhibition to extend tissue plasminogen activator treatment for ischemic disease
CN107976481B (zh) * 2017-11-01 2020-04-07 广西壮族自治区食品药品检验所 一种中药材中钪含量的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319955B1 (en) 1998-01-06 2001-11-20 The General Hospital Corporation Use of MEK1 inhibitors as protective agents against damage due to ischemia
WO2006130090A1 (en) 2005-06-03 2006-12-07 Pronas Pharma Ab Use of a substance which inhibits endothelin type b and 5-hydroxytryptamine type 1b receptor upregulation in the treatment of ischemic disorders
PL2139512T3 (pl) * 2007-03-30 2013-09-30 Pronas Pharma Ab Inhibitory zaburzenia lub choroby niedokrwiennej

Also Published As

Publication number Publication date
EP2139512B1 (en) 2013-04-24
US8273771B2 (en) 2012-09-25
ES2421605T3 (es) 2013-09-04
EP2139512A4 (en) 2010-06-02
WO2008121044A1 (en) 2008-10-09
EP2139512A1 (en) 2010-01-06
US20100152248A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
HK1176601A1 (zh) 抑制劑
EP2225667A4 (en) REAL TIME COMMENTARY UNIT
ZA201004942B (en) Ptrrolopyrazine kinase inhibitors
GB201000648D0 (en) Phosphodiesterase 10 inhibitors
DK200800103A (en) Integreret føringskant for vindturbineblad
IL202616A0 (en) Substituted imidazoheterocycles
ZA201001683B (en) Substituted piperidino-dihydrothienopyrimidines
ZA200909138B (en) Met for holding files or balts
GB2455905B (en) Retaining formation
GB0701574D0 (en) Wave-dissipating block
PL2139512T3 (pl) Inhibitory zaburzenia lub choroby niedokrwiennej
EP2177529A4 (en) NEW DE-SECRETASE INHIBITOR
ZA200908943B (en) Pyrazolopyrimidinone kinase inhibitor
EP2222662A4 (en) INHIBITORS OF KYNURENINE AMINO TRANSFERASE
IL200965A0 (en) Substituted tetrahydropyrroloquinolines
GB0714941D0 (en) Inhibitors
GB0806623D0 (en) My leener
KG1098C1 (en) Towel-drying construction
GB0713152D0 (en) Phosphodlesterase inhibitors
GB0719041D0 (en) Slab
GB0806777D0 (en) Recessed steel lintels
GB0707493D0 (en) Novel inhibitors
GB0707632D0 (en) Novel inhibitors
GB0707488D0 (en) Novel inhibitors
GB0707499D0 (en) Novel inhibitors